Target Product Selection - Where Can Molecular Pharming Make the Difference?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|31|5478-5485

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.31, 2013-09, pp. : 5478-5485

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Candesartan cilexetil can make a difference to MACE rates

By  

Inpharma, Vol. 1, Iss. 1647, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

UK health challenges: can the EU make a difference?

By Madelin Robert  

Clinical Medicine, Vol. 6, Iss. 5, 2006-10 ,pp. : 493-496

Royal College Of Physicians

Access to resources Recommend Favorite

The ligand paradox between affinity and efficacy: can you be there and not make a difference?

By Kenakin T.   Onaran O.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 6, 2002-06 ,pp. : 275-280

Elsevier

Access to resources Recommend Favorite

Seeds as a Production System for Molecular Pharming Applications: Status and Prospects

By  

Current Pharmaceutical Design, Vol. 19, Iss. 31, 2013-09 ,pp. : 5543-5552

Bentham Science Publishers

Access to resources Recommend Favorite

Hospital Selection for Unit Cost Estimates in Multicentre Economic Evaluations: Does the Choice of Hospitals Make a Difference?

By Goeree R.  

PharmacoEconomics, Vol. 15, Iss. 6, 1999-06 ,pp. : 561-572

Adis International

Access to resources Recommend Favorite